Kodiak Sciences Q3 EPS Forecast Increased by HC Wainwright

Key Points

• HC Wainwright raised its Q3 2025 earnings estimate for Kodiak Sciences to ($1.05) per share, up from a previous estimate of ($1.09), maintaining a "Neutral" rating and a target price of $5.00.
• JPMorgan upgraded Kodiak Sciences from "underweight" to "neutral" with a price objective of $15.00, while Barclays increased its target from $4.00 to $7.00.
• Kodiak Sciences has a market capitalization of $500.75 million, with a one-year stock price range from $1.92 to $11.60, and approximately 89.06% of the stock is owned by institutional investors.

Kodiak Sciences Inc. (NASDAQ:KOD - Free Report) - Equities research analysts at HC Wainwright lifted their Q3 2025 earnings per share (EPS) estimates for shares of Kodiak Sciences in a research report issued on Monday, August 18th. HC Wainwright analyst M. Caufield now expects that the company will earn ($1.05) per share for the quarter, up from their prior estimate of ($1.09). HC Wainwright currently has a "Neutral" rating and a $5.00 target price on the stock. The consensus estimate for Kodiak Sciences' current full-year earnings is ($3.45) per share. HC Wainwright also issued estimates for Kodiak Sciences' Q4 2025 earnings at ($1.05) EPS, FY2025 earnings at ($4.21) EPS, FY2026 earnings at ($4.45) EPS, FY2027 earnings at ($4.40) EPS, FY2028 earnings at ($3.42) EPS and FY2029 earnings at ($1.87) EPS.

Kodiak Sciences (NASDAQ:KOD - Get Free Report) last issued its quarterly earnings data on Wednesday, August 13th. The company reported ($1.03) earnings per share for the quarter, missing analysts' consensus estimates of ($1.01) by ($0.02).

Other equities research analysts have also recently issued reports about the company. Barclays upped their price objective on Kodiak Sciences from $4.00 to $7.00 and gave the stock an "underweight" rating in a research note on Thursday, August 14th. JPMorgan Chase & Co. upgraded Kodiak Sciences from an "underweight" rating to a "neutral" rating and set a $15.00 price objective for the company in a research note on Thursday, August 14th. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Kodiak Sciences presently has a consensus rating of "Hold" and a consensus price target of $11.75.

Kodiak Sciences Stock Down 3.1%

Shares of NASDAQ KOD traded down $0.3190 during mid-day trading on Wednesday, reaching $9.8810. 187,324 shares of the company were exchanged, compared to its average volume of 445,614. The stock has a market cap of $521.91 million, a price-to-earnings ratio of -2.61 and a beta of 2.41. Kodiak Sciences has a 1 year low of $1.92 and a 1 year high of $11.60. The firm has a 50-day moving average of $6.18 and a 200 day moving average of $4.55.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Headlands Technologies LLC raised its stake in shares of Kodiak Sciences by 256.4% in the second quarter. Headlands Technologies LLC now owns 8,083 shares of the company's stock worth $30,000 after purchasing an additional 5,815 shares during the last quarter. Bridgeway Capital Management LLC raised its stake in shares of Kodiak Sciences by 8.2% in the second quarter. Bridgeway Capital Management LLC now owns 101,900 shares of the company's stock worth $380,000 after purchasing an additional 7,700 shares during the last quarter. Adage Capital Partners GP L.L.C. raised its stake in shares of Kodiak Sciences by 55.1% in the second quarter. Adage Capital Partners GP L.L.C. now owns 2,055,707 shares of the company's stock worth $7,668,000 after purchasing an additional 730,000 shares during the last quarter. Ameriprise Financial Inc. raised its stake in shares of Kodiak Sciences by 171.3% in the second quarter. Ameriprise Financial Inc. now owns 266,354 shares of the company's stock worth $994,000 after purchasing an additional 168,192 shares during the last quarter. Finally, Nantahala Capital Management LLC raised its stake in shares of Kodiak Sciences by 11.3% in the second quarter. Nantahala Capital Management LLC now owns 590,884 shares of the company's stock worth $2,204,000 after purchasing an additional 60,171 shares during the last quarter. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.